Article
Pharmacology & Pharmacy
Helen Haixia Wu, Kerry-Leigh Ralph, Eliud Sepuldeva, Gale Hansen, Hua Li, Zhong-Fu Huang, Dongmei Liu, Michael Dziegelewski, Jennifer Ahlberg, Lee Frego, Steve Fogal, Susan van Tongeren, Christine Grimaldi, Tobias Litzenberger, David Presky, Sanjaya Singh, Scott Brodeur, Rachel Kroe-Barrett
Summary: The study presents a novel antibody BI 655064 targeting the CD40-CD40L pathway, which effectively neutralizes the pathogenesis of related diseases and has high therapeutic potential.
INTERNATIONAL JOURNAL OF PHARMACEUTICS
(2021)
Article
Gastroenterology & Hepatology
Benjamin D. McDonald, Emma C. Dyer, David T. Rubin
Summary: IL-23 plays a role in multiple inflammatory disorders, and anti-IL-12/23 therapy has shown good efficacy in IBD, with emerging selective anti-IL-23 specific therapies. A biomarker-driven approach may soon guide clinicians in prescribing anti-IL-23 therapy to patients most likely to respond.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Multidisciplinary Sciences
Fan Yang, Zhenqiang He, Hao Duan, Duo Zhang, Juehui Li, Huijuan Yang, Jay F. Dorsey, Wei Zou, S. Ali Nabavizadeh, Stephen J. Bagley, Kalil Abdullah, Steven Brem, Lin Zhang, Xiaowei Xu, Katelyn T. Byrne, Robert H. Vonderheide, Yanqing Gong, Yi Fan
Summary: This study demonstrates that IL-6 blockade, in combination with a CD40 agonist, overcomes macrophage-mediated immunosuppression and sensitizes glioblastoma to immune checkpoint blockade in preclinical models, providing promising opportunities for GBM and other solid tumors.
NATURE COMMUNICATIONS
(2021)
Article
Immunology
S. P. Deo-Gracias Berry, Camille Dossou, Ali Kashif, Niusha Sharifinejad, Gholamreza Azizi, Haleh Hamedifar, Araz Sabzvari, Zeineb Zian
Summary: This review highlights the role of IL-17 in chronic inflammation occurring in allergy, malignancy, and autoimmune diseases, and discusses the potential therapeutic approach of targeting IL-17 and/or IL-17R using monoclonal antibodies (mAbs).
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Ting Yu, Yingxian Shi, Xinyan Pan, Qiang Feng, Peng Wang, Shuling Song, Lilin Yang, Julun Yang
Summary: In this study, the cell membrane penetrating peptide BR2 was used to deliver a broad-spectrum anti-p21Ras scFv gene into ganglioside expressing tumor cells. The fusion protein BR2-p21Ras scFv was found to specifically penetrate into tumor cells and bind with p21Ras, resulting in significant inhibition of tumor cell proliferation, migration, and colony formation, as well as promotion of apoptosis. This study suggests that BR2-p21Ras scFv has potential as a therapeutic antibody for ras-driven tumors.
Article
Biochemistry & Molecular Biology
Ji Won Min, Yoo-Jin Shin, Hyeyoung Lee, Bo-Mi Kim, Ki Hyun Park, Kyoung Chan Doh, Tae-Min Kim, Sun Woo Lim, Chul Woo Yang, Eun-Jee Oh, Byung Ha Chung
Summary: Inhibition of BAFF can reduce HLA.A2-specific IgG, alter the proportions of B cells in the bone marrow and spleen, and decrease specific immune responses. This suggests that BAFF suppression may be a useful target for desensitization therapy research and development.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Immunology
Shixin Duan, Jun Wang, Xinyi Lou, Dongxin Chen, Peiyunfeng Shi, Hongchao Jiang, Zhiming Wang, Wen Li, Feng Qian
Summary: IL-33 is an important member of the IL-1 family and plays a crucial role in modulating inflammatory responses. The researchers developed an effective anti-human IL-33 monoclonal antibody named 5H8, which binds to the FVLHN epitope of IL-33 and inhibits its biological activity. In vitro and in vivo experiments showed that 5H8 suppressed IL-33-induced IL-6 expression and relieved HDM-induced asthma and PR8-induced acute lung injury. The study also demonstrated that 5H8 has good thermal stability and high affinity. These findings suggest that 5H8 has potential as a therapeutic antibody for inflammatory diseases.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Medicine, Research & Experimental
Yan Wang, Chunyan Liu, Nanyang Zhang, Xianqin Song, Yu Song, Duo Cai, Kehua Fang, Xiaotian Chang
Summary: The monoclonal anti-PADI4 antibody prepared in this study showed therapeutic effects on breast tumors by inhibiting the citrullination of fibronectin, thereby altering the tumor tissue microenvironment. The antibody treatment suppressed tumor growth, increased apoptotic cells, and decreased the expression of EMT-related genes in tumors.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Multidisciplinary Sciences
Jialiang Wang, Kuirong Mao, Xiuxiu Cong, Huizhu Tan, Chenxi Wu, Zheng Hu, Yong-Guang Yang, Tianmeng Sun
Summary: In this study, a biodegradable nanoparticle delivery system was developed to effectively deliver siCD40 into various cells, leading to down-regulation of CD40 expression and inhibition of cell differentiation, resulting in prolonged allograft survival.
Article
Immunology
Valentina Ceglia, Sandra Zurawski, Monica Montes, Mitchell Kroll, Aurelie Bouteau, Zhiqing Wang, Jerome Ellis, Botond Z. Igyarto, Yves Levy, Gerard Zurawski
Summary: CD40 is an activating receptor that regulates B and T cell immunity. Fusing CD40L to anti-CD40 antibodies enhances the agonistic activity and immune response.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Gastroenterology & Hepatology
Simon Wabitsch, Mayank Tandon, Benjamin Ruf, Qianfei Zhang, Justin D. McCallen, John C. McVey, Chi Ma, Benjamin L. Green, Laurence P. Diggs, Bernd Heinrich, Tim F. Greten
Summary: The study demonstrated that trametinib enhances the immunogenicity of tumor cells by up-regulating MHC-I surface expression and when combined with anti-PD-1, resulted in optimal treatment efficacy for iCCA, particularly in SB1 tumor models. Whole-exome sequencing of SB1 cells suggests that even KRAS wild-type iCCAs respond well to this combination therapy.
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
(2021)
Article
Medicine, General & Internal
Rachel A. Bender Ignacio, Kara W. Chew, Carlee Moser, Judith S. Currier, Joseph J. Eron, Arzhang Cyrus Javan, Mark J. Giganti, Evgenia Aga, Michael Gibbs, Herve Tchouakam Kouekam, Eva Johnsson, Mark T. Esser, Keila Hoover, Gene Neytman, Matthew Newell, Eric S. Daar, William Fischer, Courtney V. Fletcher, Jonathan Z. Li, Alexander L. Greninger, Robert W. Coombs, Michael D. Hughes, Davey Smith, David Alain Wohl
Summary: These two clinical trials showed that tixagevimab and cilgavimab monoclonal antibodies were safe and effective for treating early COVID-19, but did not change the time to symptom improvement. The treatment outcomes were better for the intramuscular injection.
Article
Immunology
Basudev Paudyal, Adam McNee, Pramila Rijal, B. Veronica Carr, Alejandro Nunez, John McCauley, Rodney S. Daniels, Alain R. Townsend, John A. Hammond, Elma Tchilian
Summary: Prophylactic intravenous administration of specific monoclonal antibodies in pigs showed significant reduction in lung pathology and virus loads, but not consistent reduction in nasal shedding. The effect on lung pathology and virus load is consistent across different doses, suggesting that lower doses may be effective in reducing disease severity.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Elizabeth England, D. Gareth Rees, Ian Christopher Scott, Sara Carmen, Denice T. Y. Chan, Catherine Chaillan E. Huntington, Kirsty F. Houslay, Teodor Erngren, Mark Penney, Jayesh B. Majithiya, Laura Rapley, Dorothy A. Sims, Claire Hollins, Elizabeth C. Hinchy, Martin D. Strain, Benjamin P. Kemp, Dominic J. Corkill, Richard D. May, Katherine A. Vousden, Robin J. Butler, Tomas Mustelin, Tristan J. Vaughan, David C. Lowe, Caroline Colley, E. Suzanne Cohen
Summary: This study identified a drug called tozorakimab, a monoclonal antibody that inhibits interleukin-33 through different signaling pathways. It effectively reduces inflammation and epithelial dysfunction.
SCIENTIFIC REPORTS
(2023)
Article
Dermatology
L. Mastorino, S. Susca, C. Cariti, N. Sliquini, A. Verrone, E. Stroppiana, M. Ortoncelli, P. Dapavo, S. Ribero, P. Quaglino
Summary: Many European national guidelines recommend initial treatment with anti-TNF-alpha adalimumab for psoriasis and psoriatic arthritis due to economic reasons. This study evaluated the efficacy and safety of IL-17 and IL-23 inhibitors for patients who had previously received adalimumab treatment compared to adalimumab-naive patients. The findings suggested that there were no significant differences in efficacy between IL-17 and IL-23 inhibitors for both adalimumab-experienced and adalimumab-naive patients.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
(2023)
Review
Immunology
Kyohei Nakamura, Mark J. Smyth
CELLULAR & MOLECULAR IMMUNOLOGY
(2020)
Article
Oncology
Juming Yan, Stacey Allen, Elizabeth McDonald, Indrajit Das, Jeffrey Y. W. Mak, Ligong Liu, David P. Fairlie, Bronwyn S. Meehan, Zhenjun Chen, Alexandra J. Corbett, Antiopi Varelias, Mark J. Smyth, Michele W. L. Teng
Article
Oncology
Juming Yan, Xian-Yang Li, Amelia Roman Aguilera, Christos Xiao, Celia Jacoberger-Foisac, Bianca Nowlan, Simon C. Robson, Courtney Beers, Achim K. Moesta, Nishamol Geetha, Michele W. L. Teng, Mark J. Smyth
CANCER IMMUNOLOGY RESEARCH
(2020)
Article
Oncology
Ailin Lepletier, Jason Madore, Jake S. O'Donnell, Rebecca L. Johnston, Xian-Yang Li, Elizabeth McDonald, Elizabeth Ahern, Anna Kuchel, Melissa Eastgate, Sally-Ann Pearson, Domenico Mallardo, Paolo A. Ascierto, Daniela Massi, Barbara Merelli, Mario Mandala, James S. Wilmott, Alexander M. Menzies, Charles Leduc, John Stagg, Bertrand Routy, Georgina Long, Richard A. Scolyer, Tobias Bald, Nicola Waddell, William C. Dougall, Michele W. L. Teng, Mark J. Smyth
CLINICAL CANCER RESEARCH
(2020)
Editorial Material
Dermatology
Tobias Bald, Mark J. Smyth
JOURNAL OF INVESTIGATIVE DERMATOLOGY
(2020)
Review
Hematology
Kyohei Nakamura, Mark J. Smyth, Ludovic Martinet
Editorial Material
Cell Biology
Kyohei Nakamura, Tobias Bald, Mark J. Smyth
IMMUNOLOGY AND CELL BIOLOGY
(2020)
Article
Cell Biology
Camille Guillerey, Kimberley Stannard, Jason Chen, Sophie Krumeich, Kim Miles, Kyohei Nakamura, Jessica Smith, Yuan Yu, Susanna Ng, Heidi Harjunpaa, Michele W. L. Teng, Christian Engwerda, Gabrielle T. Belz, Mark J. Smyth
Summary: The study found that the growth of multiple myeloma was associated with changes in BM ILC2s, characterized by increased expression of maturation markers and reduced cytokine response. A subset of KLRG1(hi)ILC2s which preferentially accumulated in the liver and spleen was identified.
IMMUNOLOGY AND CELL BIOLOGY
(2021)
Review
Immunology
Tobias Bald, Matthew F. Krummel, Mark J. Smyth, Kevin C. Barry
Article
Immunology
Susanna S. Ng, Fabian De Labastida Rivera, Juming Yan, Dillon Corvino, Indrajit Das, Ping Zhang, Rachel Kuns, Shashi Bhushan Chauhan, Jiajie Hou, Xian-Yang Li, Teija C. M. Frame, Benjamin A. McEnroe, Eilish Moore, Jinrui Na, Jessica A. Engel, Megan S. F. Soon, Bhawana Singh, Andrew J. Kueh, Marco J. Herold, Marcela Montes de Oca, Siddharth Sankar Singh, Patrick T. Bunn, Amy Roman Aguilera, Mika Casey, Matthias Braun, Nazanin Ghazanfari, Shivangi Wani, Yulin Wang, Fiona H. Amante, Chelsea L. Edwards, Ashraful Haque, William C. Dougall, Om Prakash Singh, Alan G. Baxter, Michele W. L. Teng, Alex Loukas, Norelle L. Daly, Nicole Cloonan, Mariapia A. Degli-Esposti, Jude Uzonna, William R. Heath, Tobias Bald, Siok-Keen Tey, Kyohei Nakamura, Geoffrey R. Hill, Rajiv Kumar, Shyam Sundar, Mark J. Smyth, Christian R. Engwerda
Article
Oncology
Charles Lin, Trishna Ballah, Michelle Nottage, Karen Hay, Benjamin Chua, Lizbeth Kenny, Paul Thomas, Michele Teng, Jacqui Keller, Trang Le, Jennifer Edmunds, Brett Hughes
Summary: This study aims to investigate the efficacy of combining curative intent chemoradiation with the PD-L1 inhibitor durvalumab for patients with unresectable advanced cSCC, focusing on complete response rate and treatment safety.
RADIATION ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Paolo A. Ascierto, Christian Blank, Reinhard Dummer, Marc S. Ernstoff, Soldano Ferrone, Bernard A. Fox, Thomas F. Gajewski, Claus Garbe, Patrick Hwu, Pawel Kalinski, Michelle Krogsgaard, Roger S. Lo, Jason J. Luke, Bart Neyns, Michael A. Postow, Sergio A. Quezada, Michele W. L. Teng, Giorgio Trinchieri, Alessandro Testori, Corrado Caraco, Iman Osman, Igor Puzanov, Magdalena Thurin
Summary: Advances in immune checkpoint therapy and targeted therapy have improved overall survival for patients with advanced melanoma, but challenges remain in patient classification, therapy selection, and prediction of treatment response. Understanding tumor microenvironment, immunity, and therapy response drives translational and clinical research in melanoma.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Gastroenterology & Hepatology
Christina Nalkurthi, Wayne A. Schroder, Michelle Melino, Katharine M. Irvine, Melanie Nyuydzefe, Wei Chen, Jing Liu, Michele W. L. Teng, Geoffrey R. Hill, Patrick Bertolino, Bruce R. Blazar, Gregory C. Miller, Andrew D. Clouston, Alexandra Zanin-Zhorov, Kelli P. A. MacDonald
Summary: By administrating a selective ROCK2 inhibitor, the prevention and reversal of hepatic fibrosis can be achieved through its effects on pro-inflammatory immune cell function. This study sheds light on the therapeutic potential of ROCK2 targeting in chronic liver disease and provides insights into the cellular and molecular pathways driving liver fibrosis.
Article
Oncology
Celia Jacoberger-Foissac, Stephen J. Blake, Jing Liu, Elizabeth McDonald, Hannah Triscott, Kyohei Nakamura, Mark J. Smyth, Michele W. L. Teng
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2020)
Review
Immunology
Achim K. Moesta, Xian-Yang Li, Mark J. Smyth
NATURE REVIEWS IMMUNOLOGY
(2020)